Vitiligo-like depigmentation associated with metastatic melanoma of an unknown origin

Annals of Dermatology

Volumn 21, Issue 2, 2009, Pages 178-181

  Cho, Eun Ah ^a   Lee, Myung Ah ^a   Kang, Hoon ^a   Lee, Seung Dong ^a   Kim, Hyung Ok ^a   Park, Young Min ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Metastatic melanoma; Vitiligo like depigmentation

Indexed keywords

EID: 73449138388     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2009.21.2.178     Document Type: Article

References (16)

1. Ortonne JP, Gauthier Y, Guillet G, Gauthier O. Hypomela-nosis of the skin and malignant melanoma. Ann Dermatol Venereol 1978;105:1043-1052.
2. Duhra P, llchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991;16:303-305.
3. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983;9:689-696.
4. Kiecker F, Hofmann M, Sterry W, Trefzer U. Vitiligo-like depigmentation as a presenting sign of metastatic melanoma. J Eur Acad Dermatol Venereol 2006;20:1135-1137.
5. Berd D, Mastrangelo MJ, Lattime E, Sato T, Maguire HC Jr. Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunol Immunother 1996;42:263-267.
6. Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma. A case study. Dermatologica 1991;183:239-245.
7. Merimsky O, Shoenfeld Y, Yecheskel G, Chaitchik S, Azizi E, Fishman P. Vitiligo- and melanoma-associated hypo pigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 1994;38:411-416.
8. Arpaia N, Cassano N, Vena GA. Regressing cutaneous malignant melanoma and vitiligo-like depigmentation. Int J Dermatol 2006;45:952-956.
9. Cui J, Bystryn JC. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995;131:314-318.
10. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000;192:1637-1644.
11. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, et al. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol 2001;117:1464-1470.
12. Hornung MO, Krementz ET. Specific tissue and tumor responses of chimpanzees following immunization against human melanoma. Surgery 1974;75:477-486.
13. Cui J, Chen D, Misfeldt ML, Swinfard RW, Bystryn JC. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995;8:60-63.
14. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008;35:433-444.
15. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987;123:1053-1055.
16. Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 1983;9:696-708.